Headache News and Research

Latest Headache News and Research

MRI reveals changes in brains of people with post-concussion syndrome

MRI shows changes in the brains of people with post-concussion syndrome (PCS), according to a new study published online in the journal Radiology. Researchers hope the results point the way to improved detection and treatment for the disorder.

21 Nov 2012

Novartis receives FDA approval for Flucelvax to prevent seasonal influenza

The U.S. Food and Drug Administration announced today the approval of Flucelvax, the first seasonal influenza vaccine licensed in the United States produced using cultured animal cells, instead of fertilized chicken eggs. Flucelvax is approved to prevent seasonal influenza in people ages 18 years and older.

21 Nov 2012

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).

20 Nov 2012

Positive results from Genentech Avastin plus temozolomide Phase III study on glioblastoma

Genentech, a member of the Roche Group, today announced results from the positive Phase III AVAglio study. The study showed Avastin (bevacizumab) in combination with radiation and temozolomide chemotherapy reduced the risk of cancer worsening or death (progression-free survival; PFS) by 36 percent compared to radiation and temozolomide chemotherapy plus placebo>th Annual Meeting of the Society for Neuro-Oncology in Washington, D.C.

19 Nov 2012

Latest in optometry: headache link debunked; iPads open up new vista

The latest research in optometry finds no link between headaches and refractive errors in children under the age of 18 years – and a clinical purpose for iPads.

16 Nov 2012

Study examines how anxiety sensitivity thwarts efforts of smokers with asthma to quit smoking

A new University of Cincinnati study examines how anxiety sensitivity can thwart the efforts of smokers with asthma to quit smoking. This new direction of research from Alison McLeish, a UC assistant professor of psychology, will be presented on Nov.17, at the 46th annual convention of the Association of Behavioral and Cognitive Therapies (ABCT) in National Harbor, Md.

15 Nov 2012

Is it safe to drink alcohol when taking antibiotics?

In the lead up to summer party season, NPS MedicineWise is reminding Australians that while alcohol might not interact with many antibiotics, it’s still important to follow certain rules for taking antibiotics correctly.

15 Nov 2012

Ebola, Marburg and Lassa viruses must be designated as emerging diagnoses

The Ebola, Marburg and Lassa viruses are commonly referred to as emerging diseases, but leading scientists say these life-threatening viruses have been around for centuries.

15 Nov 2012

Minor symptoms a big deal in nasal polyposis

Asthma does not have any significant influence on quality of life among patients with nasal polyposis, but it may increase the intensity of individual minor symptoms such as headache, or fullness in the ears, report researchers.

14 Nov 2012

With votes counted, the 'fiscal cliff' looms large

News outlets report that with the election in the rear-view mirror, President Barack Obama and congressional lawmakers must pivot to high-stakes negotiations over expiring income tax rates, massive scheduled cuts to Pentagon spending and entitlement reform. Also on the to-do list: the Medicare doc-fix.

8 Nov 2012

Teva announces additional data from QNASL Phase III program on seasonal allergic rhinitis

Teva Pharmaceutical Industries Ltd. announced today that additional data from the Phase III clinical program for QNASL- (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2012 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, CA on November 8-13, 2012.

7 Nov 2012

Positive results from Santarus and Pharming’s RUCONEST Phase III trial on HAE

Santarus, Inc. and Pharming Group NV today announced that their pivotal Phase III clinical study to evaluate the safety and efficacy of the investigational drug RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg for the treatment of acute attacks of angioedema in patients with Hereditary Angioedema (HAE) met the primary endpoint of time to beginning of symptom relief.

7 Nov 2012

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

6 Nov 2012

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

6 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Baylor University receives two new federal grants for research on Gulf War illness

Baylor University has been awarded two new federal grants for research on Gulf War illness, the complex medical condition that affects veterans of the 1991 war. The grants, from the Office of Congressionally Directed Medical Research Programs of the U.S. Department of Defense, total nearly $1.6 million, and bring current federal funding for Baylor's Gulf War research program to over $2.3 million.

3 Nov 2012

TD-1211 may relieve opioid-induced constipation

TD-1211 – an inhibitor of the mµ-opioid receptor – alleviates chronic noncancer-related constipation in patients receiving opioid therapy, without affecting pain relief, show the results of a parallel-group study.

2 Nov 2012

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Gilead Sciences, Inc. today announced that a Phase 2 clinical trial evaluating tenofovir alafenamide fumarate, an investigational novel prodrug of tenofovir for the treatment of HIV-1 infection, met its primary objective.

1 Nov 2012

Children with migraine more likely to have below average school performance

Children with migraine are more likely to have below average school performance than kids who do not have headaches, according to new research published in the October 30, 2012, print issue of Neurology-, the medical journal of the American Academy of Neurology.

30 Oct 2012

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.

29 Oct 2012